Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Lecanemab (Leqembi) and donanemab (Kisunla) have both received FDA approval as amyloid-beta targeting therapies.⁷⁻⁸ Several ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Korea must embrace gender innovation to combat drug discrimination and promote equity Korean researchers urged to prioritize ...